Talis Biomedical Corp Price Prediction
At this time the relative strength index (rsi) of Talis Biomedical's share price is below 20 . This usually implies that the pink sheet is significantly oversold. The fundamental principle of the Relative Strength Index (RSI) is to quantify the velocity at which market participants are driving the price of a financial instrument upwards or downwards.
The successful prediction of Talis Biomedical's future price could yield a significant profit. Please, note that this module is not intended to be used solely to calculate an intrinsic value of Talis Biomedical and does not consider all of the tangible or intangible factors available from Talis Biomedical's fundamental data. We analyze noise-free headlines and recent hype associated with Talis Biomedical Corp, which may create opportunities for some arbitrage if properly timed.
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.
Oversold Vs Overbought
0
Oversold | Overbought |
Using Talis Biomedical hype-based prediction, you can estimate the value of Talis Biomedical Corp from the perspective of Talis Biomedical response to recently generated media hype and the effects of current headlines on its competitors.
The fear of missing out, i.e., FOMO, can cause potential investors in Talis Biomedical to buy its pink sheet at a price that has no basis in reality. In that case, they are not buying Talis because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell pink sheets at prices well below their value during bear markets because they need to stop feeling the pain of losing money.
Talis Biomedical after-hype prediction price | USD 0.0 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as pink sheet price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Talis |
Talis Biomedical After-Hype Price Prediction Density Analysis
As far as predicting the price of Talis Biomedical at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Talis Biomedical or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Pink Sheet prices, such as prices of Talis Biomedical, with the unreliable approximations that try to describe financial returns.
Next price density |
Expected price to next headline |
Talis Biomedical Estimiated After-Hype Price Volatility
In the context of predicting Talis Biomedical's pink sheet value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Talis Biomedical's historical news coverage. Talis Biomedical's after-hype downside and upside margins for the prediction period are 0.00 and 37.74, respectively. We have considered Talis Biomedical's daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
Talis Biomedical is out of control at this time. Analysis and calculation of next after-hype price of Talis Biomedical Corp is based on 3 months time horizon.
Talis Biomedical Pink Sheet Price Prediction Analysis
Have you ever been surprised when a price of a Company such as Talis Biomedical is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Talis Biomedical backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Pink Sheet price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Talis Biomedical, there might be something going there, and it might present an excellent short sale opportunity.
Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
18.11 | 37.74 | 0.00 | 1.41 | 0 Events / Month | 8 Events / Month | Within a week |
Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | ||
0.00 | 0.00 | 0.00 |
|
Talis Biomedical Hype Timeline
Talis Biomedical Corp is at this time traded for 0.00. The entity stock is not elastic to its hype. The average elasticity to hype of competition is 1.41. Talis is forecasted not to react to the next headline, with the price staying at about the same level, and average media hype impact volatility is insignificant. The immediate return on the next news is forecasted to be very small, whereas the daily expected return is at this time at -18.11%. %. The volatility of related hype on Talis Biomedical is about 48576.24%, with the expected price after the next announcement by competition of 1.41. About 52.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 0.06. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Talis Biomedical Corp recorded a loss per share of 28.02. The entity had not issued any dividends in recent years. The firm had 1:15 split on the 6th of July 2023. Given the investment horizon of 90 days the next forecasted press release will be within a week. Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.Talis Biomedical Related Hype Analysis
Having access to credible news sources related to Talis Biomedical's direct competition is more important than ever and may enhance your ability to predict Talis Biomedical's future price movements. Getting to know how Talis Biomedical's peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Talis Biomedical may potentially react to the hype associated with one of its peers.
HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
TIVC | Tivic Health Systems | (0.01) | 7 per month | 0.00 | (0.03) | 12.12 | (6.90) | 79.31 | |
BJDX | Bluejay Diagnostics | 0.45 | 3 per month | 0.00 | (0.1) | 13.03 | (13.14) | 120.52 | |
HSCS | Heart Test Laboratories | 0.33 | 3 per month | 0.00 | (0.04) | 11.44 | (8.97) | 58.33 | |
NUWE | Nuwellis | 0.58 | 4 per month | 12.27 | 0.04 | 25.66 | (25.00) | 141.14 | |
BBLG | Bone Biologics Corp | (0.13) | 2 per month | 8.76 | 0.04 | 18.13 | (17.14) | 163.17 | |
INVO | INVO Bioscience | 0.57 | 3 per month | 4.69 | 0.02 | 6.67 | (6.85) | 105.62 | |
TNON | Tenon Medical | (0.23) | 8 per month | 7.91 | 0.01 | 34.08 | (16.00) | 90.53 | |
MOTS | Motus GI Holdings | 0.00 | 0 per month | 0.00 | (0.04) | 9.09 | (5.63) | 56.89 | |
BVS | Bioventus | (0.22) | 10 per month | 3.66 | 0.08 | 5.34 | (4.82) | 26.44 | |
SGHT | Sight Sciences | (0.05) | 8 per month | 0.00 | (0.20) | 6.96 | (7.84) | 18.22 | |
SSKN | STRATA Skin Sciences | (0.03) | 10 per month | 3.83 | 0.05 | 8.83 | (7.20) | 20.44 | |
NPCE | Neuropace | (0.25) | 10 per month | 3.21 | 0.06 | 9.73 | (6.19) | 35.38 | |
VAPO | Vapotherm | 0.00 | 0 per month | 0.00 | (0.05) | 15.38 | (11.63) | 34.31 |
Talis Biomedical Additional Predictive Modules
Most predictive techniques to examine Talis price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Talis using various technical indicators. When you analyze Talis charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.Cycle Indicators | ||
Math Operators | ||
Math Transform | ||
Momentum Indicators | ||
Overlap Studies | ||
Pattern Recognition | ||
Price Transform | ||
Statistic Functions | ||
Volatility Indicators | ||
Volume Indicators |
About Talis Biomedical Predictive Indicators
The successful prediction of Talis Biomedical stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Talis Biomedical Corp, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Talis Biomedical based on analysis of Talis Biomedical hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to Talis Biomedical's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Talis Biomedical's related companies.
Story Coverage note for Talis Biomedical
The number of cover stories for Talis Biomedical depends on current market conditions and Talis Biomedical's risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that Talis Biomedical is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about Talis Biomedical's long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.
Contributor Headline
Latest Perspective From Macroaxis
Talis Biomedical Short Properties
Talis Biomedical's future price predictability will typically decrease when Talis Biomedical's long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of Talis Biomedical Corp often depends not only on the future outlook of the potential Talis Biomedical's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Talis Biomedical's indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding | 1.8 M | |
Cash And Short Term Investments | 76.7 M |
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Other Consideration for investing in Talis Pink Sheet
If you are still planning to invest in Talis Biomedical Corp check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Talis Biomedical's history and understand the potential risks before investing.
Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities |